Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell Alzheon Stock

Alzheon Stock

alzheon.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $90.97MM

Alzheon is a biopharmaceutical company striving to develop treatments designed for patients with Alzheimer’s Disease and other neurodegenerative disorders. Alzheon was founded in 2013 and is headquartered in Framingham, MA. Their leading candidate, ALZ-801, is an oral anti-amyloid treatment aimed at slowing or preventing Alzheimer’s disease, particularly in patients with specific genetic markers.

Buy or sell Alzheon stockLearn more about Alzheon IPO

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Alzheon, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Alzheon’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alzheon.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Alzheon investors also invested in these private companies

Ally Bridge Group
Thornapple River Capital
The National Institute on Aging (NIA)
HCL Capital
Aptorum Group

Team

Management Team

Martin Tolar MD Ph.D
Founder, President & Chief Executive Officer
John Hey Ph.D
Chief Scientific Officer
Susan Abushakra MD
Chief Medical Officer
Aidan Power
Chief Development Officer
Kenneth Mace
Chief Financial Officer
Glenn Pauly
Chief Commercial Officer
Adem Albayrak
Chief of Staff

Alzheon stock FAQs

plusminus

Can you buy Alzheon stock?

As Alzheon is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Alzheon, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy Alzheon stock?

To invest in a private company like Alzheon through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Alzheon stock?

Yes, you may be able to sell your Alzheon stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Alzheon stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Alzheon stock on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is Alzheon a public company?

No, Alzheon is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Alzheon’s stock price?

Alzheon is a privately held company and therefore does not have a public stock price. However, you may access Alzheon’s private market stock price with Forge Data.
plusminus

What is Alzheon’s stock ticker symbol?

Alzheon does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Alzheon in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
Element Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.05B
Genengnews 06/12/2024

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

In a series E funding round Alzheon raised $100 million.
wbjournal 12/08/2023

Alzheon bolsters executive staff in preparation for launch of new Alzheimer’s drug

Alzheon, a biopharmaceutical company, has promoted Glenn Pauly to chief commercial officer and appointed two new vice presidents ahead of the commercial launch of a new investigational drug, ALZ-801, which could potentially slow or prevent early Alzheimer’s disease. The company anticipates a successful commercial launch in 2025.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.